Fisher, J;
Anderson, J;
(2018)
Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy.
[Review].
Frontiers in Immunology
, 9
, Article 1409. 10.3389/fimmu.2018.01409.
Preview |
Text
fimmu-09-01409.pdf - Published Version Download (527kB) | Preview |
Abstract
Sharing both innate and adaptive immune properties, γδT cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as γδT cells represents one such approach. γδT cells can be modified using many of the techniques used in αβT cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from γδT cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, γδT cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
| Type: | Article |
|---|---|
| Title: | Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fimmu.2018.01409 |
| Publisher version: | http://doi.org/10.3389/fimmu.2018.01409 |
| Language: | English |
| Additional information: | Copyright © 2018 Fisher and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| Keywords: | gamma delta, chimeric antigen receptor, adoptive transfer, alpha beta T cells, cancer immunotherapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10053105 |
Archive Staff Only
 |
View Item |
